用于进行性多灶性白质脑病风险评估的抗JCV抗体指数的纵向分析。
Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy.
作者信息
Salmen A, von Ahsen N, Trampe A K, Hoepner R, Plavina T, Subramanyam M, Kuesters G, Gold R, Chan A
机构信息
Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany.
Medizinisches Labor Bremen, Germany.
出版信息
Mult Scler J Exp Transl Clin. 2016 Feb 8;2:2055217316630008. doi: 10.1177/2055217316630008. eCollection 2016 Jan-Dec.
Risk assessment for natalizumab-associated progressive multifocal leukoencephalopathy (Nat-PML) comprises the anti-JC virus (JCV) antibody index (AI). The anti-JCV AI was longitudinally determined in a natalizumab-treated MS cohort (Nat-MS, = 468) and samples of Nat-PML patients ( = 15). In Nat-MS, the median AI was 0.8 (25th to 75th percentile, 0.2-2.8) with an intra-individual coefficient of variation (CV) of 9.8% (4.8-17.6). Patients with an AI ≤ 0.9 exhibited higher CV. The AI was higher (3.4 (3.1-3.6)) in samples before Nat-PML diagnosis than in seropositive Nat-MS (2.4 (1.0-3.4), = 298, = 0.010). AIs ≥ 3.0 were associated with a 14.5-fold (95% CI 2.3-90.4) increased PML risk ( = 0.002). Groups with an AI below 1.5 exhibit higher variability or even serostatus fluctuation. AI dynamics require further investigation.
那他珠单抗相关的进行性多灶性白质脑病（Nat-PML）的风险评估包括抗JC病毒（JCV）抗体指数（AI）。在接受那他珠单抗治疗的多发性硬化症队列（Nat-MS，n = 468）和Nat-PML患者样本（n = 15）中纵向测定抗JCV AI。在Nat-MS中，AI中位数为0.8（第25至75百分位数，0.2 - 2.8），个体内变异系数（CV）为9.8%（4.8 - 17.6）。AI≤0.9的患者表现出更高的CV。在Nat-PML诊断前的样本中，AI更高（3.4（3.1 - 3.6）），高于血清阳性的Nat-MS（2.4（1.0 - 3.4），n = 298，P = 0.010）。AI≥3.0与PML风险增加14.5倍（95%CI 2.3 - 90.4）相关（P = 0.002）。AI低于1.5的组表现出更高的变异性甚至血清状态波动。AI动态变化需要进一步研究。
Zotero 插件